Women Have Less Access to Kidney Transplant Waitlist
Interventions may be needed to achieve gender and racial equity in access to kidney transplantation across end-stage renal disease networks in the United States.
Race Differences
ADPKD Progression to End-Stage Kidney Disease Varies by Race/Ethnicity
Autosomal dominant polycystic kidney disease progresses to kidney failure faster in Hispanic patients than in those of other races or ethnicities, a study found.
COVID-19 Vaccine Hesitancy in the Dialysis Population Characterized
The overriding concern of vaccine-hesitant patients related to side effects, followed by doubts about the efficacy of a vaccine, and discomfort with vaccines in general, according to investigators.
Why Racial and Ethnic Disparities Exist in Kidney Disease Care
Lack of timely referrals to nephrologists contribute to racial and ethnic disparities in kidney disease care.
British Study Reveals No Race Disparity in Survival in mCRPC Cases
Overall, Black and White men with metastatic castration-resistant prostate cancer had similar median overall survival times, according to a British study.
Time From eGFR Wait-List Threshold to ESKD Shorter in Blacks
Registering Blacks on transplant wait list at eGFR of 24 to 25 mL/min/1.73 m2 could improve racial equity in wait time prior to ESKD onset
Male Urge Urinary Incontinence Prevalence Differs by Race
Experiencing any urinary incontinence was associated with bother regardless of a man’s race.
Excess Deaths Higher Among Black, Hispanic Patients With ESKD During Pandemic
Investigators say inequities in the social determinants of health likely explain the racial and ethnic disparities.
Survival Benefit With First-Line Abiraterone for mCRPC Superior in Black Men
New real-world data suggest the presence of race-based differences in the therapeutic response to abiraterone.
Enzalutamide for mHSPC Improves Outcomes, Especially in Black Men
Black men with metastatic hormone-sensitive prostate cancer may have better outcomes if they receive enzalutamide rather than bicalutamide in combination with androgen deprivation therapy, data from a phase 2 trial suggests.
-
Loading...
-
Loading...
Next post in Prostate Cancer
